QBTS or RGTI: Which Quantum Stock Stands Out on $2B Federal Fund?

The U.S. Commerce Department issued letters of intent totaling about $2.013B in proposed CHIPS and Science Act incentives to nine quantum-related companies, with D-Wave Quantum (QBTS) and Rigetti Computing (RGTI) each eligible for up to $100M. The announcement lifted QBTS 14.6% and RGTI 22.6%, while the article argues QBTS has the stronger near-term case due to commercial traction, a $10M enterprise contract, and higher implied upside of 32.39% versus 25.91% for RGTI. Valuations remain stretched, with forward P/S at 178.18x for QBTS and 248.0x for RGTI.

Analysis

The federal awards matter less as direct cash than as a de-risking event for the entire quantum equity complex. The bigger second-order effect is that government validation can pull forward enterprise procurement conversations, because large customers tend to treat public-sector backing as a credibility filter for a still-unproven category. That favors the name with near-term use-case monetization and penalizes the one whose value still depends on a longer technical runway.

QBTS has the cleaner bridge from narrative to revenue because it can translate attention into contracts and usage now, not just roadmap milestones. The market is likely to keep paying a premium for any proof that quantum can move from lab demos to workflow optimization, but that premium is already rich, so upside now depends on continued booking wins rather than the headline grant itself. RGTI’s setup is more path-dependent: the funding reduces dilution risk and supports R&D throughput, but the stock still needs a sequence of technical inflection points to justify further re-rating.

The contrarian read is that the post-announcement move may be front-loading several quarters of good news. In names trading at extreme sales multiples, the main failure mode is not bad headlines but the absence of incremental catalysts after the initial policy pop fades. If the sector rotates from “policy optionality” to “show me revenue,” QBTS should hold up better, while RGTI is more exposed to a fast unwind if milestone cadence slips.

The cleanest tactical edge is not directional beta chasing, but relative-value exposure to the stronger commercialization profile versus the higher-duration research story. Quantum as a basket may remain volatile for months, but dispersion should widen once the market stops rewarding the whole theme indiscriminately and starts discriminating on contract conversion and dilution discipline.

Key Decisions for Investors

• Long QBTS / short RGTI as a 1-3 month relative-value pair: expressed on equal dollar exposure, thesis is that policy validation plus near-term commercial traction should outperform a longer-duration R&D story if the quantum basket cools.
• If adding outright exposure, prefer QBTS on pullbacks rather than chasing momentum: use a 2-4 week entry window and size for high volatility; risk/reward is better tied to contract/news flow than to the federal announcement itself.
• Avoid fresh long RGTI at current levels unless you have a 6-12 month horizon and can tolerate drawdowns: the trade only works if technical milestones arrive on schedule, otherwise multiple compression can dominate funding optimism.
• For event-risk control, consider call spreads instead of stock in QBTS over the next 1-2 quarters: upside participates in follow-on adoption, while defined risk protects against post-rally mean reversion.
• Fade the sector basket if no new commercial wins emerge within 4-8 weeks: the policy catalyst is largely digested, and the next leg likely requires actual revenue conversion rather than another headline.